These warnings mainly apply after prostate biopsy—not after imaging-only TRUS
Seek Urgent Help for Fever, Inability to Urinate or Heavy Bleeding After Biopsy
Contact the treating team urgently or attend emergency care after a prostate biopsy if you develop:
- Fever, shaking chills, confusion, marked weakness or feeling suddenly very unwell.
- Difficulty breathing, fainting, collapse or cold, clammy skin.
- Inability to pass urine, painful lower-abdominal swelling or worsening urinary difficulty.
- Heavy or persistent blood in urine or from the rectum, large clots, or bleeding with dizziness.
- Severe or rapidly worsening pelvic, perineal, rectal or lower-abdominal pain.
These can indicate infection, sepsis, urinary retention or significant bleeding. Do not wait for a routine result.
A diagnostic TRUS alone should not cause fever, heavy bleeding or inability to urinate; seek assessment if any of
these occurs after any prostate procedure.
First Check: Is This a Scan or a Biopsy?
Diagnostic TRUS / prostate-volume scan
A covered, lubricated ultrasound probe is placed in the rectum to make images and measurements. There is
no needle, no tissue removal and usually no antibiotic or recovery period.
TRUS-guided transrectal biopsy
The same type of probe provides live images while biopsy needles pass through the rectal wall to take tissue
cores. Local anaesthetic, infection precautions, medicine review and specific aftercare are required.
TRUS-guided transperineal biopsy
The ultrasound probe may still be in the rectum, but biopsy needles enter through cleaned skin between the
scrotum and anus. This route has a lower infectious risk and is preferred in many current pathways.
MRI-targeted biopsy
A suspicious area identified on prostate MRI is targeted during ultrasound-guided biopsy by cognitive
matching or software fusion. It may be combined with systematic or nearby sampling.
“TRUS” Describes the Imaging Route, Not Automatically a Needle Route
If your form only says “TRUS,” ask whether it is an imaging-only prostate-volume scan, a biopsy or another
guided procedure. Never follow biopsy instructions—or stop medicines—unless the procedure team has confirmed
that tissue sampling is actually planned.
Where is the Prostate, and Why Use a Rectal Probe?
The prostate lies below the bladder, surrounds the first part of the urethra and sits immediately in front of the
rectum. A transrectal probe can therefore be placed close to the gland, producing more detailed prostate images and
volume measurements than a probe on the lower abdomen in many patients.
Peripheral zone
Forms much of the back and outer gland. Many prostate cancers arise here, but normal ultrasound appearance
cannot exclude cancer.
Transition zone
Surrounds the urethra and commonly enlarges in benign prostatic hyperplasia (BPH), sometimes compressing
the urinary channel.
Central zone and anterior tissue
Complete the gland's internal anatomy. Their appearance and symmetry are reviewed, but ultrasound is less
specific than MRI for characterising many focal abnormalities.
Seminal vesicles and ejaculatory ducts
Structures behind the prostate that contribute fluid to semen. Dilatation, asymmetry, cysts, stones or
obstruction may be relevant in selected patients.
Why Might Diagnostic TRUS Be Requested?
Accurate prostate volume
For BPH assessment, PSA density, medicine decisions or planning a prostate procedure.
Abnormal PSA or examination
As one component of assessment—usually alongside clinical review and prostate MRI when appropriate.
Procedure guidance
To guide biopsy, fiducial markers, brachytherapy, drainage or another selected intervention.
Seminal-tract concern
For selected cases of blood in semen, low-volume ejaculate, ejaculatory-duct obstruction or infertility.
Other reasons can include:
- Lower urinary tract symptoms with uncertainty about prostate size or shape.
- Measuring a median lobe or intravesical prostatic protrusion when relevant to treatment planning.
- Suspected prostatic abscess or another collection, particularly when cross-sectional imaging is unavailable or guidance is needed.
- Review of a cyst, calcification or focal finding seen on another examination.
- Planning or follow-up in a known prostate-cancer pathway.
The indication should be specific. A diagnostic TRUS is not a general screening test for everyone with urinary
symptoms, and it cannot diagnose prostate cancer by appearance alone.
What Does the Radiologist Assess?
Three dimensions and calculated volume
Length, width and height are measured in orthogonal planes. The machine uses an ellipsoid calculation to
estimate volume, reported in cubic centimetres (cc) or millilitres (mL).
Contour, symmetry and zones
The gland outline, internal pattern and relative enlargement of the transition zone are reviewed in axial
and sagittal views.
Median lobe and relationship to the bladder
Upward protrusion of prostate tissue toward the bladder may be documented when visible and clinically relevant.
Focal lesions, cysts and calcifications
Their location, size and ultrasound appearance are recorded. None of these features alone proves or excludes cancer.
Seminal vesicles and ejaculatory ducts
The structures are assessed for symmetry, dilatation, cystic change, stones, inflammation or a possible obstructive pattern.
Vascularity and procedure route
Colour Doppler may assess blood flow, while real-time imaging can map a safe path for biopsy or another guided procedure.
What is PSA Density?
PSA density (PSAD) relates the blood PSA value to the size of the prostate. It is calculated by dividing PSA in
ng/mL by prostate volume in cc. For example, a PSA of 6 ng/mL and a prostate volume of 40 cc gives a PSA density
of 0.15 ng/mL/cc.
Why volume matters
A larger benign gland can produce more PSA. Relating PSA to volume can refine risk assessment, especially
when combined with MRI and the rest of the clinical picture.
Why one cut-off is not a diagnosis
PSA density thresholds vary with the MRI result, guideline and patient risk. Age, family history, PSA trend,
examination, infection, previous biopsy and MRI all influence the decision.
Why measurements can differ
MRI, transabdominal ultrasound and TRUS may estimate volume differently. Irregular gland shape, probe
pressure and calliper placement can also cause small differences.
Do not use an online PSA-density calculation to decide whether you need biopsy. The clinician must confirm the
PSA date, volume method, recent infection or instrumentation and the full risk profile.
How is TRUS Different From Other Prostate Tests?
Digital rectal examination (DRE)
A clinician feels the back surface of the prostate for size, firmness, asymmetry or nodules. It does not
provide an image or accurate volume.
PSA and other blood tests
Estimate risk but do not show anatomy. PSA can rise with cancer, BPH, inflammation, infection and recent manipulation.
Transabdominal urinary ultrasound
Uses a lower-abdominal probe, usually with a full bladder, to assess kidneys, bladder, post-void residual
and an approximate prostate size. It is less detailed for internal prostate anatomy.
Transrectal prostate ultrasound
Places the probe close to the gland for detailed real-time images, volume measurement and procedure guidance.
It cannot reliably characterise or exclude cancer.
Multiparametric prostate MRI
Better characterises suspicious areas and local anatomy before biopsy in modern cancer pathways. It is
commonly used to select and target biopsy sites.
Biopsy and histopathology
Tissue examination determines whether cancer is present and, if so, its grade. Imaging cannot substitute
for histology when biopsy is clinically required.
Cystoscopy
A camera examines the urethra and bladder. It answers different questions and does not image the prostate zones.
How Should I Prepare?
Preparation depends entirely on whether the appointment is for imaging only or includes a biopsy. Read the
procedure name on the booking letter and call the department if it is unclear.
For diagnostic TRUS only
You can usually eat, drink and take regular medicines normally. Little or no special preparation is
needed. Some departments request a small enema, but this is not universal.
Bladder preparation
A full bladder is usually unnecessary for TRUS alone. It may be requested if a transabdominal bladder or
post-void residual scan is being performed at the same visit.
If biopsy is planned
Follow the separate written plan for infection checks, antibiotics when indicated, bowel preparation,
food and drink, anaesthesia and travel home. Requirements differ by biopsy route and local protocol.
Blood thinners and antiplatelet medicines
Never stop an antiplatelet, anticoagulant or another prescribed medicine yourself.
The procedure team must balance bleeding against the risk of a clot and give an individual plan.
Tell the team in advance about:
- Fever, burning urine, cloudy urine, a current urinary infection or recent antibiotics.
- Active heavy rectal bleeding, severe rectal pain, a fissure, inflamed haemorrhoids, proctitis or inflammatory bowel disease.
- Previous rectal surgery, radiotherapy, narrowing, an absent rectum or difficulty tolerating rectal examinations.
- A bleeding disorder or any anticoagulant, antiplatelet or non-prescribed supplement that affects clotting.
- Allergy to latex, antiseptic, antibiotics or local anaesthetic.
- A prosthetic heart valve, implanted device or another condition relevant to antibiotic or procedural planning.
The team may postpone a routine examination if active infection, severe proctitis or significant rectal bleeding
makes it unsafe or poorly tolerated. Do not conceal symptoms to keep the appointment.
What Happens During an Imaging-Only TRUS?
1
The exact procedure is confirmed
The team checks the referral, symptoms, PSA and previous imaging and confirms that this is a diagnostic scan
rather than a biopsy. Consent, privacy and a chaperone are addressed.
2
You change and lie on your side
Clothing below the waist is removed or adjusted and you are covered appropriately. Most patients lie on
the left side with knees comfortably bent toward the chest.
3
A rectal examination may be performed
A gentle finger examination may check for tenderness, narrowing or a palpable prostate abnormality before
the ultrasound probe is inserted.
4
The covered probe is inserted
A slim, finger-sized transducer is covered with a protective sheath, lubricated and passed a short distance
into the rectum. Slow insertion and communication help minimise discomfort.
5
Images and measurements are recorded
The probe is turned gently to obtain axial and sagittal views. Prostate dimensions, volume, zones, seminal
vesicles and any relevant finding are documented, with Doppler when useful.
6
You can leave immediately afterward
The probe is removed and you dress in privacy. Diagnostic TRUS usually needs no sedation, recovery period
or activity restriction.
The scan commonly takes 10–20 minutes. It may feel like pressure, fullness or the urge to open your bowels, but
it should not cause severe pain. Tell the radiologist immediately if you are uncomfortable; the examination can
be paused or stopped.
If a Biopsy is Planned, What is Different?
A prostate biopsy is an invasive tissue-sampling procedure. Local anaesthetic is used, the biopsy device makes a
brief clicking sound and several slender cores are placed in labelled containers for pathology. Samples may be
systematic, MRI-targeted, perilesional or a planned combination.
Transrectal needle route
The needle crosses the rectal wall. Infection-prevention measures and antibiotics are determined by local
policy and individual risk because bowel bacteria can enter deeper tissue or blood.
Transperineal needle route
Needles pass through cleaned perineal skin while TRUS guides their position. Many services favour this
route because infectious complications are lower, although soreness and temporary urinary difficulty can occur.
Expected after-effects
Mild soreness and some blood in urine, semen or stool can occur. The discharge instructions should state
what amount and duration are expected and whom to call if symptoms exceed them.
Pathology result
Ultrasound guides the needle but does not determine the diagnosis. The laboratory report on the tissue
cores provides the cancer diagnosis and grade when cancer is present.
This guide does not replace the biopsy consent and aftercare sheet. Follow the procedure team's instructions even
when they differ from preparation for an imaging-only scan. Our
Prostate Biopsy guide explains needle routes,
MRI targeting, tissue results and complications separately.
What Do Common Report Terms Mean?
Prostate volume: ___ cc / mL
The calculated gland size. One cc is equivalent to one mL for this purpose. Size helps assess BPH, PSA
density and suitability for selected procedures but does not measure symptom severity by itself.
Prostatomegaly / enlarged prostate
The gland is larger than expected. This commonly reflects benign enlargement, but the clinical context
still determines whether further investigation is needed.
Transition-zone hyperplasia / BPH
Benign nodular enlargement around the urethra. It can contribute to poor flow, urgency, incomplete emptying
or retention, although size and symptoms do not always match.
Median lobe / intravesical prostatic protrusion
Prostate tissue projects upward at the bladder outlet. This may influence obstruction assessment and procedure choice.
Heterogeneous echotexture
The internal ultrasound pattern is mixed rather than uniform. BPH, inflammation, fibrosis, calcifications
and previous treatment can all cause this non-specific appearance.
Hypoechoic focus or lesion
An area appears darker than surrounding tissue. Cancer is one possibility, but inflammation, infarction
and benign nodules can look similar; many cancers are not distinctly dark on TRUS.
Calcifications / concretions
Bright mineral deposits, often related to age, ducts or previous inflammation. They are common and usually
do not require treatment by themselves.
Prostatic or midline cyst
A fluid-filled space. Its location, size and relationship to the urethra or ejaculatory ducts determine
whether it is incidental or potentially obstructive.
Seminal-vesicle asymmetry or dilatation
One side differs in size or a vesicle appears enlarged. Ejaculatory timing, inflammation, obstruction and
congenital variation are considered with symptoms and semen analysis.
Abscess / collection
A suspected pocket of infected fluid. Fever, pain and systemic illness require prompt clinical treatment;
imaging may guide drainage in selected cases.
Capsule appears intact
No obvious disruption is seen on ultrasound. This does not exclude microscopic spread outside the prostate
and is not a complete cancer-stage assessment.
PSA density
PSA divided by prostate volume. It modifies risk assessment but is not a stand-alone cancer test or a
universal biopsy threshold.
What Can TRUS Not Determine Reliably?
- Whether prostate cancer is present or absent from ultrasound appearance alone.
- Whether a dark (hypoechoic) area is cancer; benign inflammation and nodules can look similar.
- Whether an apparently normal gland contains cancer, because many cancers are isoechoic or too subtle to see.
- The complete location and biological significance of a suspicious focus as accurately as modern multiparametric MRI.
- Microscopic extension through the capsule, perineural spread, lymph-node disease or bone metastases.
- Whether an abnormal PSA comes from BPH, inflammation, cancer or another cause without the full clinical work-up.
- The severity of urinary obstruction from prostate size alone; flow rate, residual urine, symptoms and bladder function also matter.
- All bladder, ureter or kidney disease, because TRUS is not a complete urinary-tract examination.
- A perfectly reproducible volume when the gland is irregular or different equipment, pressure and calliper methods are used.
A reassuring TRUS can answer the question it was designed to address, but it must not be used to cancel clinically
indicated PSA follow-up, MRI, biopsy, cystoscopy or urological assessment.
How Does TRUS Fit Into a Modern Prostate-Cancer Pathway?
1
Risk is assessed
PSA, PSA trend, age, family history, ancestry, urinary or infection history and digital rectal examination
are considered together.
2
Prostate MRI is performed when appropriate
Current major guidelines recommend MRI before biopsy for suspected localised disease. MRI maps suspicious
areas and contributes to the decision about whether and where to sample.
3
TRUS supplies live procedural imaging
The ultrasound probe shows the gland in real time and helps align systematic, MRI-targeted or perilesional
cores, whether the needle route is transrectal or transperineal.
4
Pathology establishes the diagnosis
Tissue cores are examined for cancer type, grade group and extent in the samples. Imaging, pathology and
clinical findings are then reviewed together.
Local pathways differ. Some people with a low-suspicion MRI and low overall clinical risk may avoid immediate
biopsy after shared decision-making, while a negative MRI does not remove the need for biopsy when suspicion remains high.
Common Findings and Their Usual Next Steps
Benign prostatic enlargement
Symptoms, urine flow, residual volume, kidney function and patient preference guide treatment. A large
volume alone does not mandate an operation.
Calcifications or a small uncomplicated cyst
Frequently incidental. Follow-up or treatment is considered only when location, symptoms or another
clinical feature makes the finding relevant.
Possible prostatitis or abscess
Symptoms, examination, urine and blood tests determine urgency. A collection with systemic infection may
require admission, intravenous treatment and drainage.
Seminal-vesicle or ejaculatory-duct change
Correlated with semen volume, fertility assessment, blood in semen, pain and sometimes MRI, endoscopy or
other targeted testing.
Indeterminate focal lesion
Does not equal cancer. PSA risk, examination, MRI and, when indicated, biopsy determine the next step.
Myth vs Fact
Myth
Every TRUS appointment includes a prostate biopsy.
Fact
Diagnostic TRUS uses only an ultrasound probe. A biopsy is a separate invasive procedure with specific
consent, preparation and aftercare.
Myth
A normal TRUS rules out prostate cancer.
Fact
Many cancers are not visibly distinct on ultrasound. PSA risk, MRI and biopsy pathology answer different questions.
Myth
A prostate-biopsy needle must pass through the rectum.
Fact
In transperineal biopsy the needle passes through cleaned perineal skin, although a rectal ultrasound
probe may still guide it.
Myth
Every patient needs fasting, a full bladder and an enema.
Fact
Imaging-only TRUS usually needs little preparation. Biopsy and combined urinary scans have different,
locally specified instructions.
Myth
A hypoechoic focus on TRUS is definitely cancer.
Fact
Dark areas are non-specific and can represent inflammation or benign change. Conversely, cancer can
be isoechoic and invisible on TRUS.
Myth
Blood after biopsy is always an emergency.
Fact
Small amounts can be expected, but heavy or persistent bleeding, large clots, faintness, retention,
fever or feeling very unwell requires urgent advice.
Frequently Asked Questions
Does diagnostic TRUS hurt?
Most people describe pressure or fullness rather than pain. Slow insertion, lubrication and communication
improve comfort. Tell the radiologist about a fissure, painful haemorrhoids or previous rectal surgery beforehand.
Do I need to fast or arrive with a full bladder?
Usually neither for imaging-only TRUS. A full bladder may be requested for an additional transabdominal or
post-void scan, and food restrictions may apply if sedation or another procedure is planned. Follow the booking letter.
Will I need sedation?
Not for a standard diagnostic scan. Local anaesthetic or, less commonly, sedation or anaesthesia may be used
for biopsy or another intervention according to the route and protocol.
How large is the probe?
The inserted part is commonly described as about finger-sized. It is covered with a protective sheath and
lubricated before being passed a short distance into the rectum.
Can I have TRUS if I have haemorrhoids?
Mild, non-inflamed haemorrhoids do not always prevent scanning. Active heavy bleeding, severe pain, thrombosis,
proctitis or narrowing may require postponement or an alternative. Tell the team before the appointment.
Could a biopsy be added without telling me?
No. Biopsy requires a specific clinical decision, consent, medicine and infection review, local anaesthesia and
aftercare. Confirm the planned procedure before it begins and ask whenever the wording on the form is unclear.
Do I need an MRI before prostate biopsy?
Major current guidelines recommend pre-biopsy MRI for suspected localised prostate cancer when appropriate.
Exceptions exist—for example, clearly advanced disease or an individual unable to undergo MRI—so the urologist
selects the pathway.
Is a transperineal biopsy still “TRUS-guided”?
It can be. “Transperineal” describes where the needle enters; “TRUS-guided” describes the live image from the
rectal ultrasound probe. The two terms are not contradictory.
What is the infection risk after biopsy?
Infection can occur after either route but is lower with transperineal biopsy. Fever, chills, confusion or
feeling very unwell after any biopsy needs urgent assessment rather than waiting for the pathology result.
Is blood in semen expected after biopsy?
A reddish, brown or rust colour can persist for several weeks and is often harmless after biopsy. Follow the
discharge sheet and seek advice for heavy bleeding, severe pain, fever or symptoms that concern you.
Can TRUS explain infertility or low semen volume?
In selected patients it can show seminal-vesicle, ejaculatory-duct or midline cystic abnormalities, but semen
analysis, hormones, examination and sometimes other imaging are also needed. It is not a complete fertility test.
When will I receive the result?
The imaging report is sent to the referring clinician according to local practice. If biopsy was performed,
pathology takes longer and is discussed separately. Ask which result is pending and how it will be communicated.